BBIO - Bridgebio Pharma Inc Stock Price, Fair Value and News

$28.53+0.76 (+2.74%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

BBIO Price Action

Last 7 days

2.6%

Last 30 days

21.8%

Last 90 days

16.4%

Trailing 12 Months

-30.5%

BBIO RSI Chart

BBIO Valuation

Market Cap

5.4B

Price/Earnings (Trailing)

-12.08

Price/Sales (Trailing)

24.5

Price/Free Cashflow

-11.94

BBIO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

BBIO Fundamentals

BBIO Revenue

Revenue (TTM)

220.1M

Rev. Growth (Yr)

-33.22%

Rev. Growth (Qtr)

26.01%

BBIO Earnings

Earnings (TTM)

-446.3M

Earnings Growth (Yr)

8.49%

Earnings Growth (Qtr)

-117.43%

BBIO Profitability

Operating Margin

98.91%

Return on Equity

36.61%

Return on Assets

-67.11%

Free Cashflow Yield

-8.37%

BBIO Investor Care

Shares Dilution (1Y)

8.64%

Diluted EPS (TTM)

-2.41

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	196.8M	219.0M	220.1M	0
2023	130.2M	152.4M	174.6M	0
2022	79.3M	88.8M	98.4M	107.9M
2021	23.6M	39.0M	54.3M	69.7M
2020	0	0	24.4M	8.2M
2019	0	0	0	40.6M

Get all data in R, Python etc through our Historical Stock Data APIs

About Bridgebio Pharma Inc

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

CEO	Dr. Neil Kumar Ph.D.
WEBSITE	bridgebio.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	392

Bridgebio Pharma Inc Frequently Asked Questions

What is the ticker symbol for Bridgebio Pharma Inc? What does BBIO stand for in stocks?

BBIO is the stock ticker symbol of Bridgebio Pharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bridgebio Pharma Inc (BBIO)?

As of Tue Dec 24 2024, market cap of Bridgebio Pharma Inc is 5.39 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BBIO stock?

You can check BBIO's fair value in chart for subscribers.

Is Bridgebio Pharma Inc a good stock to buy?

The fair value guage provides a quick view whether BBIO is over valued or under valued. Whether Bridgebio Pharma Inc is cheap or expensive depends on the assumptions which impact Bridgebio Pharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BBIO.

What is Bridgebio Pharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Dec 24 2024, BBIO's PE ratio (Price to Earnings) is -12.08 and Price to Sales (PS) ratio is 24.5. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BBIO PE ratio will change depending on the future growth rate expectations of investors.